In an interview with The Center for Biosimilars®, Mona Chitre, PharmD, CGP, chief pharmacy officer and vice president of clinical operations and health innovation at Excellus Blue Cross Blue Shield, said increased spending on specialty pharmacy products is a primary reason for health plans’ growing interest in developing strategies to address biosimilars.
While multiple stakeholder groups have roles to play in biosimilar acceptance and uptake, as more biosimilars reach the US marketplace, payers are becoming a particularly important group—one that is uniquely situated to engage with other stakeholders—in shaping the US biosimilars experience.
In an interview with The Center for Biosimilars®, Mona Chitre, PharmD, CGP, chief pharmacy officer and vice president of clinical operations and health innovation at Excellus Blue Cross Blue Shield, said increased spending on specialty pharmacy products is a primary reason for health plans’ growing interest in developing strategies to address biosimilars.
Chitre explained that Excellus, like other plans, has seen a relatively small percentage of the population drive the trend toward increased spending on specialty drugs, and that spending is rising as specialty products are increasingly used to manage common diseases states with a higher prevalence. “Our goal is to ensure access and affordability of these medications to our patients, but these costs are becoming concerning,” she said.
Now that more biologics are coming off patent and biosimilars gain approval, “We have the opportunity now to introduce competition. It’s like generics of 20 years ago.”
Excellus, which Chitre notes was among the first plans to proactively address biosimilars, crafted a strategy for making the most of potential biosimilar savings that started with seeking out stakeholders’ views on and perceptions of biosimilars, then creating a plan to inform and educate each group.
Patients comprise a key part of that plan. Among non-clinicians, “the name biosimilar in itself can sometimes cause a little concern to a patient,” because the term implies that the patient’s treatment may not be the same. “It’s how we educate and overcome and inform,” said Chitre, that helps patients to gain a level of comfort with the idea of taking a biosimilar.
Among providers, Excellus found that, beyond the core needs for safety and efficacy data for biosimilars, a key issue for prescribers was the provision of equivalent copay matching programs and nursing services. Chitre said that prescribers’ emphasis on ensuring that nurses were informed about biosimilars spurred Excellus to engage with infusion nurses more closely, and that doing so was a “great opportunity” given how much interaction nurses have with patients who are undergoing treatment.
Finally, employers are a key group with whom Excellus engaged, and Chitre said that, after learning more about the potential savings that biosimilars can provide, some employers were willing to forego upfront savings in the form of rebates from brand-name drug sponsors in favor of long-term competition in the specialty drug market. “They bought in around the value of competition,” said Chitre. “It may take time, and it’s okay that we’re the first.”
Looking to the future, if biosimilars are successful, they could help provide headroom in pharmaceutical spending that will allow for new, even higher-cost therapies—such as gene or cell therapies—than products available in the market today.
“The way I think about it,” said Chitre, “is that maximizing generics gave us room for specialty,” and biosimilars could provide the much-needed room for spending on emerging treatments with even higher price tags.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.